Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.

Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, Urba WJ, Leidner RS.

J Immunother Cancer. 2019 Jul 3;7(1):165. doi: 10.1186/s40425-019-0645-6.

2.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A.

Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15.

PMID:
30988166
3.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

4.

Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer.

van de Ven R, Hilton TL, Hu HM, Dubay CJ, Haley D, Paustian C, Puri S, Urba WJ, Curti BD, Aung S, Fox BA.

Oncoimmunology. 2018 Sep 25;7(12):e1466766. doi: 10.1080/2162402X.2018.1466766. eCollection 2018.

5.

Immunotherapy in Advanced Renal Cancer - Is Cure Possible?

Curti BD.

N Engl J Med. 2018 Apr 5;378(14):1344-1345. doi: 10.1056/NEJMe1801682. Epub 2018 Mar 21. No abstract available.

PMID:
29562143
6.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

7.

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.

Koguchi Y, Hoen HM, Bambina SA, Rynning MD, Fuerstenberg RK, Curti BD, Urba WJ, Milburn C, Bahjat FR, Korman AJ, Bahjat KS.

Cancer Res. 2015 Dec 1;75(23):5084-92. doi: 10.1158/0008-5472.CAN-15-2303.

8.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
9.

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.

Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, Urba WJ, Curti BD, Bifulco CB, Fox BA.

J Immunother Cancer. 2015 Oct 20;3:47. doi: 10.1186/s40425-015-0091-z. eCollection 2015.

10.

Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.

Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, Alderson KA, Sungur CM, Ames E, Mirsoian A, Reddy A, Alexander W, Soulika A, Blazar BR, Longo DL, Wiltrout RH, Murphy WJ.

Immunity. 2015 Aug 18;43(2):240-50. doi: 10.1016/j.immuni.2015.06.023. Epub 2015 Jul 28.

11.

Clinical deployment of antibodies for treatment of melanoma.

Curti BD, Urba WJ.

Mol Immunol. 2015 Oct;67(2 Pt A):18-27. doi: 10.1016/j.molimm.2015.01.025. Epub 2015 Mar 6. Review.

PMID:
25746916
12.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

13.

Rapid evolution of combination therapy in melanoma.

Curti BD.

N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158. No abstract available.

PMID:
25390744
14.

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.

Payne R, Glenn L, Hoen H, Richards B, Smith JW 2nd, Lufkin R, Crocenzi TS, Urba WJ, Curti BD.

J Immunother Cancer. 2014 May 14;2:13. doi: 10.1186/2051-1426-2-13. eCollection 2014.

15.

OX40 is a potent immune-stimulating target in late-stage cancer patients.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD.

Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31.

16.

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS.

J Immunother. 2013 Nov-Dec;36(9):490-5. doi: 10.1097/CJI.0000000000000003.

PMID:
24145360
17.

Integrating new therapies in the treatment of advanced melanoma.

Curti BD, Urba WJ.

Curr Treat Options Oncol. 2012 Sep;13(3):327-39. doi: 10.1007/s11864-012-0201-9. Review.

PMID:
22743761
18.

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.

Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ.

Sci Transl Med. 2012 Jun 6;4(137):137ra74. doi: 10.1126/scitranslmed.3003649.

19.

Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG.

Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD.

Eur J Immunol. 2012 Jul;42(7):1893-905. doi: 10.1002/eji.201242444.

20.

Science gone translational: the OX40 agonist story.

Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD.

Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Review.

21.

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.

Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.

Oncology. 2010;78(5-6):340-7. doi: 10.1159/000320223. Epub 2010 Aug 20.

PMID:
20733337
22.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

23.

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA.

Curr Mol Med. 2009 Aug;9(6):673-82. Review.

24.

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.

J Clin Oncol. 2008 Apr 20;26(12):2034-9. doi: 10.1200/JCO.2007.14.5193. Epub 2008 Mar 17.

PMID:
18347008
25.

Sunitinib efficacy against advanced renal cell carcinoma.

Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G.

J Urol. 2007 Nov;178(5):1883-7. Epub 2007 Sep 17.

PMID:
17868732
26.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
27.

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ, Weinberg AD.

Mol Immunol. 2007 May;44(12):3112-21. Epub 2007 Mar 19.

28.

Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.

Curti BD.

Expert Rev Anticancer Ther. 2006 Jun;6(6):905-9. Review.

PMID:
16761934
29.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
30.

Renal cell carcinoma.

Curti BD.

JAMA. 2004 Jul 7;292(1):97-100. Review. No abstract available.

PMID:
15238597
31.

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.

Janik JE, Miller LL, Korn EL, Stevens D, Curti BD, Smith JW 2nd, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL.

Blood. 2001 Apr 1;97(7):1942-6.

PMID:
11264156
32.

Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.

Cancer J. 2000 May-Jun;6(3):146-50.

PMID:
10882329
33.

Adoptive immunotherapy.

Curti BD.

Cancer Chemother Biol Response Modif. 1999;18:239-49. Review. No abstract available.

PMID:
10800486
34.

Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.

Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik JE.

Cancer J Sci Am. 2000 Jan-Feb;6(1):21-4.

PMID:
10696734
35.

Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.

Janik JE, Miller LL, Kopp WC, Taub DD, Dawson H, Stevens D, Kostboth P, Curti BD, Conlon KC, Dunn BK, Donegan SE, Ullrich R, Alvord WG, Gause BL, Longo DL.

Clin Immunol. 1999 Dec;93(3):209-21.

PMID:
10600331
36.

Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.

Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, Holmlund JT, Curti BD, Sznol M, Smith JW 2nd, Urba WJ, Donegan SE, Watson TM, Longo DL.

Blood. 1999 May 15;93(10):3250-8.

PMID:
10233876
37.

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.

Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Gause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL.

J Clin Oncol. 1998 Aug;16(8):2752-60.

PMID:
9704728
38.

A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.

Gause BL, Sharfman WH, Janik JE, Curti BD, Steis RG, Urba WJ, Smith JW 2nd, Alvord WG, Longo DL.

Cancer Invest. 1998;16(6):374-80.

PMID:
9679527
39.

Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin.

Yoe J, Gause BL, Curti BD, Longo DL, Bagg A, Kopp WC, Janik JE.

Am J Hematol. 1998 Mar;57(3):253-7.

40.

Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus.

Vortmeyer AO, Kingma DW, Fenton RG, Curti BD, Jaffe ES, Duray PH.

Am J Clin Pathol. 1998 Jan;109(1):90-5.

PMID:
9426523
41.

Interleukin 1 alpha increases serum leptin concentrations in humans.

Janik JE, Curti BD, Considine RV, Rager HC, Powers GC, Alvord WG, Smith JW 2nd, Gause BL, Kopp WC.

J Clin Endocrinol Metab. 1997 Sep;82(9):3084-6.

PMID:
9284748
42.

Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.

Saxton ML, Longo DL, Wetzel HE, Tribble H, Alvord WG, Kwak LW, Leonard AS, Ullmann CD, Curti BD, Ochoa AC.

Blood. 1997 Apr 1;89(7):2529-36.

PMID:
9116299
43.

Adoptive immunotherapy.

Curti BD.

Cancer Chemother Biol Response Modif. 1997;17:316-27. Review. No abstract available.

PMID:
9551218
44.

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74.

PMID:
8941876
45.

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.

Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW 2nd, Sharfman WH, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):296-308.

PMID:
8877723
46.

Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer.

Curti BD, Urba WJ, Longo DL, Janik JE, Sharfman WH, Miller LL, Cizza G, Shimizu M, Oppenheim JJ, Alvord WG, Smith JW 2nd.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):142-8.

PMID:
8732697
47.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd.

J Natl Cancer Inst. 1996 Jan 3;88(1):44-9.

PMID:
8847725
48.

Adoptive immunotherapy.

Curti BD.

Cancer Chemother Biol Response Modif. 1996;16:274-84. Review. No abstract available.

PMID:
8639385
49.

Alterations in T cell receptor and signal transduction molecules in melanoma patients.

Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, et al.

Clin Cancer Res. 1995 Nov;1(11):1327-35.

50.

Interleukin-1 in the treatment of cancer.

Curti BD, Smith JW 2nd.

Pharmacol Ther. 1995 Mar;65(3):291-302. Review.

PMID:
7644565

Supplemental Content

Loading ...
Support Center